JPET #172742 1 The Novel Pyrrolidine nor-Lobelane Analog UKCP-110 (cis-2,5-di-(2-Phenethyl)-pyrrolidine Hydrochloride) Inhibits VMAT2 Function, Methamphetamine-evoked Dopamine Release, and Methamphetamine Self-administration in Rats

نویسندگان

  • Joshua S. Beckmann
  • Kiran B. Siripurapu
  • Justin R. Nickell
  • David B. Horton
  • Emily D. Denehy
  • Ashish Vartak
  • Peter A. Crooks
  • Linda P. Dwoskin
  • Michael T. Bardo
چکیده

Both lobeline and lobelane attenuate methamphetamine self-administration in rats by decreasing methamphetamine-induced dopamine release via interaction with the vesicular monoamine transporter-2 (VMAT2). A novel derivative of nor-lobelane, cis-2,5-di-(2phenethyl)-pyrrolidine hydrochloride (UKCP-110) and its trans-isomers, (2R,5R)-trans-di-(2phenethyl)-pyrrolidine hydrochloride (UKCP-111) and (2S,5S)-trans-di-(2-phenethyl)pyrrolidine hydrochloride (UKCP-112) were evaluated for inhibition of [H]dihydrotetrabenazine binding and [H]dopamine uptake using a rat synaptic vesicle preparation to assess VMAT2 interaction. Compounds were evaluated for inhibition of [H]nicotine and [H]methyllycaconitine binding to assess interaction with the major nicotinic receptor subtypes. Also, compounds were evaluated for inhibition of methamphetamineevoked endogenous dopamine release using striatal slices. The most promising compound, UKCP-110, was evaluated for its ability to decrease methamphetamine self-administration and methamphetamine discriminative stimulus cues, and for its effect on food-maintained operant responding. UKCP-110, UKCP-111 and UKCP-112 inhibited [H]dihydrotetrabenazine binding [Ki = 2.66 ± 0.37 μM, 1.05 ± 0.10 μM, 3.80 ± 0.31 μM, respectively], and had high potency inhibiting [H]dopamine uptake [Ki = 0.028 ± 0.001 μM, 0.046 ± 0.008 μM, 0.043 ± 0.004 μM, respectively], but lacked affinity at nicotinic receptors. While the trans-isomers did not alter methamphetamine-evoked dopamine release, UKCP110 inhibited [IC50 = 1.8 ± 0.2 μM; Imax = 67.18 ± 6.11 μM] methamphetamine-evoked dopamine release. At high concentrations, UKCP-110 also increased extracellular dihydroxyphenylacetic acid. Importantly, UKCP-110 decreased the number of methamphetamine self-infusions, while having no effect on food-reinforced behavior or the methamphetamine stimulus cue. Thus, UKCP-110 represents a new lead in the development of novel pharmacotherapies for the treatment of methamphetamine abuse. This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on August 30, 2010 as DOI: 10.1124/jpet.110.172742 at A PE T Jornals on Jauary 9, 2018 jpet.asjournals.org D ow nladed from

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats.

Both lobeline and lobelane attenuate methamphetamine self-administration in rats by decreasing methamphetamine-induced dopamine release via interaction with vesicular monoamine transporter-2 (VMAT2). A novel derivative of nor-lobelane, cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride (UKCP-110), and its trans-isomers, (2R,5R)-trans-di-(2-phenethyl)-pyrrolidine hydrochloride (UKCP-111) and (2S...

متن کامل

The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.

Methamphetamine abuse escalates, but no approved therapeutics are available to treat addicted individuals. Methamphetamine increases extracellular dopamine in reward-relevant pathways by interacting at vesicular monoamine transporter-2 (VMAT2) to inhibit dopamine uptake and promote dopamine release from synaptic vesicles, increasing cytosolic dopamine available for reverse transport by the dopa...

متن کامل

Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.

Lobelane, a chemically defunctionalized saturated analog of lobeline, has increased selectivity for the vesicular monoamine transporter 2 (VMAT2) compared with the parent compound. Lobelane inhibits methamphetamine-evoked dopamine (DA) release and decreases methamphetamine self-administration. Unfortunately, tolerance develops to the ability of lobelane to decrease these behavioral effects of m...

متن کامل

Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.

Lobeline is currently being evaluated in clinical trials as a methamphetamine abuse treatment. Lobeline interacts with nicotinic receptor subtypes, dopamine transporters (DATs), and vesicular monoamine transporters (VMAT2s). Methamphetamine inhibits VMAT2 and promotes dopamine (DA) release from synaptic vesicles, resulting ultimately in increased extracellular DA. The present study generated st...

متن کامل

Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.

Lobeline attenuates the behavioral effects of methamphetamine via inhibition of the vesicular monoamine transporter (VMAT2). To increase selectivity for VMAT2, chemically defunctionalized lobeline analogs, including lobelane, were designed to eliminate nicotinic acetylcholine receptor affinity. The current study evaluated the ability of lobelane analogs to inhibit [³H]dihydrotetrabenazine (DTBZ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2010